Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Empagliflozin for Duchenne muscular dystrophy-associated cardiomyopathy in children and adolescents
ISRCTN12497973Phase 2Active, not recruiting
- Sponsor
- UCL Great Ormond Street Institute of Child Health
- Start
- Oct 2025
- Modality
- Small Molecules
01
Overview
Phase 2, open-label, single-arm trial of empagliflozin in Cardiomyopathies and Duchenne muscular dystrophy (DMD), sponsored by UCL Great Ormond Street Institute of Child Health. Started Oct 2025; status: active, not recruiting.
02
Drugs
empagliflozin
03
Conditions
CardiomyopathiesDuchenne muscular dystrophy (DMD)
Beyond the preview
Go deeper on ISRCTN12497973.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN12497973.